MorphImmune, Inc., a Research Bridge Partners Portfolio Company, Appoints Ronald Martell as President and CEO
- Tuesday, June 8, 2021, 6:31
- Finance
- Add a comment
AUSTIN, Texas, June 8, 2021 /PRNewswire/ — MorphImmune, Inc., a Research Bridge Partners portfolio company that is advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system, announced the appointment of Ronald Martell as the…
About the Author
adminasapcorp has written 41546 stories on this site.